Interaction between amylose, a common food component, and beta-cyclodextrin (betaCD), an often used food additive, was investigated by incorporating a third component of bioactive conjugated linoleic acid (CLA) that could form an inclusion complex with both amylose and betaCD. The existence of an amylose-betaCD interaction was first evidenced by a reduced thermal stability of amylose in the amylose-betaCD complex and a decrease of extractable betaCD from 60 to 51.40% after their complexation. The way of their interaction was then explored in a three-component system, in which the amount of CLA is high enough to oversaturate both amylose and betaCD. In comparison to the amylose-CLA and betaCD-CLA complexes, a self-assemblied amylose-CLA-betaCD three-component complex confirmed by differential scanning calorimetry (DSC), X-ray diffraction, and thermogravimetric analyses showed an in-between thermal stability, high acid stability, and the highest amylolytic digestibility (74.43%), which suggests that betaCD is likely sandwiched between the helical amylose chains in the amylose-betaCD complex. Therefore, betaCD can be used to manipulate the crystallization process of amylose to modulate food product quality, and the amylose-betaCD complex could also be applied to improve the delivery efficiency of CLA and other bioactive compounds.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2010) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: